Results 11 to 20 of about 3,549 (185)

Immunogenicity Assessment of Pegfilgrastim in Patients with Breast Cancer

Разработка и регистрация лекарственных средств, 2020
Introduction. Neutropenia, which is an abnormally low concentration of neutrophils in the blood, is one of the common side effects in patients receiving radio- or chemotherapy.
Yu. V. Medvedev, M. A. Kolganova, O. A. Sas, T. N. Komarov, E. N. Fisher, I. E. Shohin, Yu. I. Ammour   +6 more
doaj   +4 more sources

Granulocyte colony-stimulating factors for febrile neutropenia prophylaxis following chemotherapy: systematic review and meta-analysis [PDF]

BMC Cancer, 2011
Background Febrile neutropenia (FN) occurs following myelosuppressive chemotherapy and is associated with morbidity, mortality, costs, and chemotherapy reductions and delays. Granulocyte colony-stimulating factors (G-CSFs) stimulate neutrophil production
Stevenson Matt D, Whyte Sophie, Madan Jason, Cooper Katy L, Akehurst Ron L   +4 more
doaj   +2 more sources

A Pilot Study to Evaluate the Role of Therapeutic Drug Monitoring of Pegfilgrastim in Lymphoma Patients Receiving Chemotherapy

Proceedings of Singapore Healthcare, 2014
Background: Despite primary prophylaxis of febrile neutropenia (FN) with pegfilgrastim, studies have demonstrated a significant number of breakthrough FN events among Asian lymphoma patients receiving chemotherapy.
Michelle See PharmD, Vivianne Lee Chuen Shih PharmD, BCPS, BCOP, Han Kiat Ho PhD, Tiffany Pooi Ling Tang MBBS, MRCP, Mohamad Farid MBBS, MMed (Internal Medicine), MRCP, Richard Hong Hui Quek MBBS, MRCP, Miriam Tao MBBS, FAMS, FHKAM, FHKCP, MRCP, Soon Thye Lim MBBS, MRCP, Alexandre Chan PharmD, MPH, BCPS, BCOP   +8 more
doaj   +2 more sources

A Rare Case of Large-Vessel Vasculitis following Checkpoint Inhibitor Therapy and Pegfilgrastim

Case Reports in Oncological Medicine, 2022
Checkpoint inhibitors (CPIs) and pegfilgrastim, a long-acting growth factor agent, are vital components of current cancer treatments. Immune-related adverse events (irAEs) such as colitis and pneumonitis are well-established toxicities associated with ...
Joseph Mort, Shipra Maheshwari, Nayanika Basu, Patrick Dillon, Kevin Brady, Harry Bear, Trish Millard   +6 more
doaj   +2 more sources

Clinical confirmation to demonstrate similarity for a biosimilar pegfilgrastim: a 3-way randomized equivalence study for a proposed biosimilar pegfilgrastim versus US-licensed and EU-approved reference products in breast cancer patients receiving myelosuppressive chemotherapy

Experimental Hematology & Oncology, 2018
Background Chemotherapy-induced neutropenia is a common result of myelosuppressive chemotherapy treatment. Infections such as febrile neutropenia (FN) are sensitive to the duration of neutropenia as well as the depth of absolute neutrophil count (ANC) at
Kalpna Desai, Priya Misra, Sanyukta Kher, Nirmesh Shah   +3 more
doaj   +2 more sources

Prophylactic pegfilgrastim reduces febrile neutropenia in ramucirumab plus docetaxel after chemoimmunotherapy in advanced NSCLC: post hoc analysis from NEJ051

Scientific Reports
Ramucirumab plus docetaxel (RD) can cause febrile neutropenia (FN), which frequently requires the prophylactic administration of pegfilgrastim. However, the effects of prophylactic pegfilgrastim on FN prevention, therapeutic efficacy, and prognosis after
Keita Miura, Ou Yamaguchi, Keita Mori, Atsushi Nakamura, Motohiro Tamiya, Tomohiro Oba, Noriko Yanagitani, Hideaki Mizutani, Takashi Ninomiya, Tomosue Kajiwara, Kentaro Ito, Akihiko Miyanaga, Daisuke Arai, Hiroaki Kodama, Kunihiko Kobayashi, Kyoichi Kaira   +15 more
doaj   +2 more sources

Higher incidence of pegfilgrastim-induced bone pain in younger patients receiving myelosuppressive chemotherapy: a real-world experience

Journal of Pharmaceutical Health Care and Sciences, 2023
Background Pegfilgrastim is widely used for the prevention of febrile neutropenia (FN) in patients receiving myelosuppressive chemotherapy for various types of cancer.
Shinya Tsuboi, Tatsuya Hayama, Katsuhiro Miura, Akihiro Uchiike, Daisuke Tsutsumi, Takashi Yamauchi, Yoshihiro Hatta, Susumu Ootsuka   +7 more
doaj   +2 more sources

Efficacy and safety analysis of once per cycle pegfilgrastim and daily lenograstim in patients with breast cancer receiving adjuvant myelosuppressive chemotherapy FEC 100: a pilot study

Therapeutics and Clinical Risk Management, 2013
Luigi Rossi,1 Federica Tomao,2 Giuseppe Lo Russo,1 Anselmo Papa,1 Federica Zoratto,1 Raffaella Marzano,3 Enrico Basso,1 Erika Giordani,1 Monica Verrico,1 Fabio Ricci,4 Giulia Pasciuti,5 Edoardo Francini,6 Silverio Tomao11Oncology Unit, ICOT Hospital ...
Rossi L, Tomao F, Lo Russo G, Papa A, Zoratto F, Marzano R, Basso E, Giordani E, Verrico M, Ricci F, Pasciuti G, Francini E, Tomao S   +12 more
doaj   +1 more source

CHEMOTHERAPY-INDUCED NEUTROPENIA IN HIV POSITIVE PATIENTS WITH LYMPHOMA: COMPARISON OF PEGFILGRASTIM WITH DAILY FILGRASTIM ADMINISTRATION.

Mediterranean Journal of Hematology and Infectious Diseases, 2012
We retrospectively compared the incidence of neutropenia  in two groups of  HIV patients with lymphoma,  who underwent chemotherapy supported by once-per-cycle administration of pegfilgrastim or by daily subcutaneous injection of filgrastim, respectively.
Luciana Teofili, Immacolata Izzi, Eugenia Rosa Nuzzolo, Giancarlo Scoppettuolo, Katleen de Gaetano Donati, Lorenza Torti, Marianna Rossi   +6 more
doaj   +5 more sources

Large‐vessel vasculitis induced by pegfilgrastim and immune checkpoint inhibitor in a patient with small‐cell lung cancer

Respirology Case Reports
A 75‐year‐old woman with stage IVB (cT3N3M1c) extensive disease small‐cell lung cancer was treated with carboplatin, etoposide, and atezolizumab. Ten days after pegfilgrastim initiation, during the second chemotherapy cycle, she experienced back pain ...
Keisuke Shiraha, Yuki Takigawa, Akiko Sato, Keiichi Fujiwara, Yuka Matsuo, Mayu Goda, Tomoyoshi Inoue, Eri Nakamura, Miho Fujiwara, Suzuka Matsuoka, Hiromi Watanabe, Kenichiro Kudo, Ken Sato, Takuo Shibayama   +13 more
doaj   +2 more sources